resources

Lupin Ltd.

NSE: LUPIN

BSE: 500257

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

2,470.40+70.8 (+2.95%)

3 Jul, 1:59 PM

Overview Analysis Statements Technicals Forecast Peers Resources

News

Annual Reports and Financial Documents

Lupin Ltd. annual reports, quarterly results, earnings call transcripts and investor presentations. All official filings in one place.

	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2108
Annual Reports	FY 2013	FY 2014	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	—	—
Quarterly Results	—	—	—	—	—	—	Mar Jun Sept Dec	Mar Jun Sept Dec	Jun Sept Dec	Mar Jun Sept Dec	Mar Jun Sept Dec	Mar Jun Sept Dec	Mar Jun Sept Dec	Mar	Dec
Conference Calls	—	—	—	—	—	—	—	—	10Feb 25May 26Aug 10Nov	13Feb 25May 9Aug 16Nov	16Feb 16May 11Aug 17Nov	14Feb 14May 13Aug 13Nov	19Feb 21May 11Aug 12Nov	17Feb 14May	—
Presentations	—	—	—	—	—	—	—	—	12Jan 28Jan 13May 11Aug 28Oct	12Jan 4Feb 19May 4Aug 10Nov	11Jan 10Feb 10May 4Aug 8Nov	8Feb 7May 6Aug 7Nov	12Feb 15May 6Aug 6Nov	12Feb 7May	—

Corporate Announcements and Regulatory Filings

Lupin Ltd. BSE/NSE disclosures, board meeting outcomes, insider trading notifications, acquisitions and other regulatory filings.

Press Release / Media Release1 Jul 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin Receives EIR from U.S. FDA for its Somerset Facility with VAI Classification.
Acquisition1 Jul 2026
Announcement under Regulation 30 (LODR)-Updates on Acquisition
Updates on acquisition of minority shareholding in Multicare Pharmaceuticals Philippines, Inc. (''MPPI''), a subsidiary company and Buyback of shares by MPPI.
Press Release / Media Release1 Jul 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin Announces EMA Approval for NaMuscla Expansion for Pediatric Indication with New Strengths.
Allotment of ESOP / ESPS30 Jun 2026
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Intimation regarding Grant of 65,251 Stock Options under Lupin Employees Stock Option Scheme 2025.
Closure of Trading Window26 Jun 2026
Closure of Trading Window
Intimation of Closure of Trading Window.
Press Release / Media Release26 Jun 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin Receives Tentative Approval from U.S. FDA for Enzalutamide Tablets.
Allotment of ESOP / ESPS22 Jun 2026
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Intimation regarding Grant of 1567591 Stock Option under Lupin Employees Stock Option Scheme 2025.
Press Release / Media Release17 Jun 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin Launches Azilsartan Medoxomil Tablets in the United States.
Press Release / Media Release8 Jun 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin Collaborates with ERN for Luforbec (beclometasone/formoterol) pMDI Launch in Spain.
Press Release / Media Release4 Jun 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin Receives Approval from U.S. FDA for Ranluspec (Ranibizumab) Injection
Allotment of ESOP / ESPS3 Jun 2026
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Intimation of allotment of 16673 equity shares under ESOP.
Press Release / Media Release3 Jun 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection.
Press Release / Media Release29 May 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin Receives Approval from U.S. FDA for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets.
Acquisition29 May 2026
Announcement under Regulation 30 (LODR)-Updates on Acquisition
Update on acquisition of minority shareholding in Multicare Pharmaceuticals Philippines, Inc.
Press Release / Media Release28 May 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin Shares Phase 1 Data on LNP8701 at the ASCO Annual Meeting 2026.
Press Release / Media Release28 May 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin''s Ankleshwar Facility Receives EIR from U.S. FDA.
Analyst / Investor Meet25 May 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation about participating in the Analyst/Institutional Investors Meet.
Press Release / Media Release22 May 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension.
Reg.24(A)-Annual Secretarial Compliance20 May 2026
Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report of Lupin Limited for the Financial year ended March 31, 2026.
Press Release / Media Release19 May 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin Makes its Debut in Dow Jones Best-in-Class Indices 2026.

Frequently Asked Questions

Where can I download the annual report of Lupin Ltd.?

Annual reports of Lupin Ltd. are available for download in the Annual Reports and Financial Documents section of the Resources tab, organised by financial year.

Where can I find the quarterly results of Lupin Ltd.?

Quarterly earnings results and presentations of Lupin Ltd. are available in the Annual Reports and Financial Documents section of the Resources tab. Detailed financials are also in the Statements tab.

Does Lupin Ltd. publish earnings call transcripts?

Earnings call transcripts of Lupin Ltd., where available, are listed in the Annual Reports and Financial Documents section of the Resources tab.

Where can I find investor presentations of Lupin Ltd.?

Investor presentations and annual day presentations of Lupin Ltd. are listed in the Resources tab under Annual Reports and Financial Documents.

What are the recent corporate announcements of Lupin Ltd.?

Corporate announcements and regulatory filings of Lupin Ltd. as submitted to BSE and NSE are available in the Corporate Announcements and Regulatory Filings section of the Resources tab.

How do I access the regulatory filings of Lupin Ltd.?

Regulatory filings including board meeting outcomes, insider trading disclosures and other exchange notifications of Lupin Ltd. are in the Corporate Announcements and Regulatory Filings section of the Resources tab.

What is the ISIN of Lupin Ltd.?

The ISIN (International Securities Identification Number) of Lupin Ltd. is INE326A01037. This is the unique identifier used across exchanges and depositories.

On which stock exchange is Lupin Ltd. listed?

Lupin Ltd. is listed on NSE and BSE. The NSE symbol is LUPIN and the BSE code is -.

Where can I find the shareholding pattern of Lupin Ltd.?

The quarterly shareholding pattern of Lupin Ltd. showing promoter, FII, DII, mutual fund and public holdings is available in the Shareholding Pattern section on the Overview tab.

How current is the data for Lupin Ltd. on Sharpely?

Share price data for Lupin Ltd. is updated as of 3 Jul 2026. Financial statements, shareholding and other fundamental data are updated after each quarterly disclosure.